keyword
https://read.qxmd.com/read/38690447/botulinum-toxin-type-a-in-the-treatment-of-raynaud-s-syndrome-a-case-report
#1
Plamen Penchev, Valentin Dobrev, Petar-Preslav Petrov, Remzi Hyusein, Vladislav Velchev, Kristiyan Georgiev
Raynaud's syndrome is characterized by paroxysmal vasospasm in the digital arterioles, following exposure to cold or stress. Pain, swelling, stiffness, and hypoesthesia are observed as manifestations. The presence of a trophic ulcer is accompanied by a range of severe manifestations. The assaults occur in three distinct phases, namely vasospastic, plethoric, and erythema. Various approaches improve the overall well-being of a patient. It is possible to differentiate between primary and secondary Raynaud's syndrome, the latter being linked to systemic diseases...
March 2024: Curēus
https://read.qxmd.com/read/38689457/parkinson-s-disease-the-dentist-s-role-as-part-of-the-healthcare-team
#2
JOURNAL ARTICLE
Liliana Ortiz Camacho, Leila Jahangiri, Jenna Iseringhausen, Gary R Goldstein
Parkinson's disease is a neurodegenerative disease that results in patients exhibiting uncontrolled movements, changes in saliva production, and difficulty in swallowing and speech. Understanding the staging of the disease and the available therapies allows dentists to treat these patients safely and with compassion to meet their oral health care needs for an optimal quality of life. This appraisal discusses Parkinson's disease as it relates to clinically relevant facts to manage and treat the oral health care needs of these patients in the short and long term including general dental care recommendations...
April 30, 2024: Journal of Prosthodontics: Official Journal of the American College of Prosthodontists
https://read.qxmd.com/read/38633105/profile-of-patients-with-maxillofacial-space-infections-and-associated-risk-factors
#3
JOURNAL ARTICLE
Srikanth Gadicherla, Kirti Manglani, Kalyana C Pentapati, Adarsh Kudva, Chithra Aramanadka, Rajaji Chandravel
OBJECTIVE: To evaluate the profile of patients operated for maxillofacial space infections and associated risk factors for the length of hospital stay. MATERIALS AND METHODS: We conducted a retrospective study among patients operated for maxillofacial infections at our center from 2010 to 2020. Information collected from the records were age, sex, type and number of spaces involved, clinical signs and symptoms (pain, swelling, toothache, sore throat, otalgia, hoarseness, headache, cough, neck swelling, rancid breath, sialorrhea, gingival swelling, muffled voice, trismus, fever, dysphagia, odynophagia, malaise, lymphadenopathy, dyspnoea, pus discharge), treatment modality, total leukocyte count, evidence of bacterial growth, comorbidities, complications if any and length of hospital stay...
2024: TheScientificWorldJournal
https://read.qxmd.com/read/38608010/clozapine-treatment-for-aggressive-behaviors-in-youths-with-neurodevelopmental-disorders
#4
JOURNAL ARTICLE
Stefano Berloffa, Gabriele Masi, Francesca Falcone, Valerio Simonelli, Antonio Narzisi, Elena Valente, Valentina Viglione, Annarita Milone, Gianluca Sesso
Objectives: The aim of this study was to assess effectiveness and tolerability of Clozapine in the treatment of aggression in youth with Neurodevelopmental Disorders. Methods: Patients were consecutively admitted at our third-level university hospital with nationwide catchment from June 2018 to October 2022, and followed up to July 2023. Eligibility criteria were as follows: (1) Autism Spectrum Disorder (ASD) and/or Intellectual Disability/Borderline Cognitive Functioning, (2) behavioral dyscontrol with physical aggression; (3) age range between 8 and 18 years; (4) clinical indication for Clozapine treatment after at least two failed trials with other Second-Generation Antipsychotics (SGAs); (5) availability of an at least 6-month-long follow-up...
April 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38537033/the-state-of-the-art-in-therapeutic-administration-of-botulinum-toxin-in-children-with-cerebral-palsy-an-integrative-review
#5
JOURNAL ARTICLE
Sandro Rachevsky Dorf, Adriana Rodrigues Fonseca, Flávio Roberto Sztajnbok, Thiffany Rodrigues Delfino de Oliveira, Linamara Rizzo Basttistella
OBJECTIVE: To describe the current state of the art in the therapeutic administration of botulinum toxin with indications, efficacy, and safety profile for children and adolescents with cerebral palsy. DATA SOURCE: An integrative review was conducted. The MEDLINE/PubMed database was searched twice within the last decade using distinct terms, and only studies written in the English language were included. The study population was limited to those aged 0-18 years...
2024: Revista Paulista de Pediatria: Orgão Oficial da Sociedade de Pediatria de São Paulo
https://read.qxmd.com/read/38524401/amyotrophic-lateral-sclerosis-and-pain-a-narrative-review-from-pain-assessment-to-therapy
#6
REVIEW
Vincenzo Pota, Pasquale Sansone, Sara De Sarno, Caterina Aurilio, Francesco Coppolino, Manlio Barbarisi, Francesco Barbato, Marco Fiore, Gianluigi Cosenza, Maria Beatrice Passavanti, Maria Caterina Pace
Amyotrophic lateral sclerosis (ALS) is the most frequent neurodegenerative disease of the motor system that affects upper and lower motor neurons, leading to progressive muscle weakness, spasticity, atrophy, and respiratory failure, with a life expectancy of 2-5 years after symptom onset. In addition to motor symptoms, patients with ALS have a multitude of nonmotor symptoms; in fact, it is currently considered a multisystem disease. The purpose of our narrative review is to evaluate the different types of pain, the correlation between pain and the disease's stages, the pain assessment tools in ALS patients, and the available therapies focusing above all on the benefits of cannabis use...
2024: Behavioural Neurology
https://read.qxmd.com/read/38470068/european-academy-of-neurology-ean-guideline-on-the-management-of-amyotrophic-lateral-sclerosis-in-collaboration-with-european-reference-network-for-neuromuscular-diseases-ern-euro-nmd
#7
JOURNAL ARTICLE
Philip Van Damme, Ammar Al-Chalabi, Peter M Andersen, Adriano Chiò, Philippe Couratier, Mamede De Carvalho, Orla Hardiman, Magdalena Kuźma-Kozakiewicz, Albert Ludolph, Christopher J McDermott, Jesus S Mora, Susanne Petri, Katrin Probyn, Evy Reviers, François Salachas, Vincenzo Silani, Ole-Bjørn Tysnes, Leonard H van den Berg, Gemma Villanueva, Markus Weber
BACKGROUND: This update of the guideline on the management of amyotrophic lateral sclerosis (ALS) was commissioned by the European Academy of Neurology (EAN) and prepared in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO-NMD) and the support of the European Network for the Cure ALS (ENCALS) and the European Organization for Professionals and Patients with ALS (EUpALS). METHODS: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the effectiveness of interventions for ALS...
March 12, 2024: European Journal of Neurology
https://read.qxmd.com/read/38465519/clinical-pharmacokinetics-of-atropine-oral-gel-formulation-in-healthy-volunteers
#8
JOURNAL ARTICLE
Madison Parrot, Bhuvanesh Yathavan, Olga Averin, Logan Hoggard, Joseph E Rower, Michael Voight, Danielle Greene, Ariel Tarrell, Aviva Whelan, Hamidreza Ghandehari, Nancy Murphy, Venkata Yellepeddi
Sialorrhea or drooling is a common problem in children and adults with neurodevelopmental disorders. It can negatively impact the quality of life due to its physical and psychological manifestations. Providers commonly prescribe atropine eye drops for topical administration to the oral mucosa, as an off-label treatment to manage sialorrhea. However, the off-label use of atropine eye drops can be associated with medication and dosing errors and systemic side effects. To address these limitations of treatment, we developed a mucoadhesive topical oral gel formulation of atropine as an alternative route to off-label administration of atropine eye drops...
March 2024: Clinical and Translational Science
https://read.qxmd.com/read/38435899/botulinum-toxin-for-the-management-of-parkinson-s-disease-a-systematic-review
#9
REVIEW
Ethan Slouha, Fadi Ibrahim, Sarah Esposito, Odelin Mursuli, Atbeen Rezazadah, Lucy A Clunes, Theofanis F Kollias
Parkinson's disease (PD) is a terminal, debilitating neurodegenerative disorder typically affecting individuals over 60. It is associated with various conditions that drastically affect the patient's quality of life (QoL). Although there is no cure for PD, its symptoms can be significantly improved and even resolved through different treatments. Mainstay treatments for PD include levodopa combined with carbidopa, dopamine agonists, and even deep brain stimulation (DBS) of the subthalamic nucleus. New treatment methods have emerged, such as botulinum toxin (BoNT), which further improve symptoms and, thus, the QoL of patients with PD...
January 2024: Curēus
https://read.qxmd.com/read/38433339/the-use-of-ipratropium-bromide-for-the-treatment-of-pediatric-sialorrhea-a-retrospective-clinical-case-series
#10
JOURNAL ARTICLE
Suhaima Tunio, Julie E Strychowsky, Agnieszka Dzioba, Peng You, Edward Madou, Breanna A Chen
OBJECTIVE: This retrospective review documents the experience of ipratropium bromide use among pediatric patients with sialorrhea at our multidisciplinary sialorrhea clinic at Children's Hospital at London Health Sciences Centre (LHSC). METHODS: A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected...
March 3, 2024: Annals of Otology, Rhinology, and Laryngology
https://read.qxmd.com/read/38369562/drooling-may-be-associated-with-dysphagia-symptoms-in-multiple-sclerosis
#11
JOURNAL ARTICLE
Merve Sapmaz Atalar, Gençer Genç, Serpil Bulut
During the process of the multiple sclerosis (MS), persons with multiple sclerosis (PwMS) may experience drooling (sialorrhea) issues that are frequently disregarded. The exact cause of drooling in PwMS is poorly understood. This study aims to assess potential risk factors for drooling seen in PwMS. The study included 20 PwMS with drooling and 19 PwMS without drooling. The participants' sociodemographic data and clinical parameters were noted. To evaluate dysphagia, fatigue, and hypersalivation, the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS), the Fatigue Severity Scale (FSS), and objective saliva flow rate measurement with cottons placed in Stensen ducts and under the tongue (swab test) were used, respectively...
February 19, 2024: Dysphagia
https://read.qxmd.com/read/38332959/pharmacologic-management-of-sialorrhea-in-neonatal-and-pediatric-patients
#12
JOURNAL ARTICLE
Caitlyn V Bradford, Avery M Parman, Peter N Johnson, Jamie L Miller
Sialorrhea, defined as an excess flow of saliva or excessive secretions, is common in patients with cerebral palsy and other neurologic disorders and is associated with clinical complications such as increased risk of local skin reactions, infections, aspiration, pneumonia, and dehydration. Upon failure of non-pharmacologic measures, clinicians have several noninvasive pharmacologic options available to manage sialorrhea. This review of the literature provides detailed descriptions of medications used, efficacy, safety, and practical considerations for use of non-injectable pharmacologic agents...
2024: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/38294288/onabotulinum-toxin-a-bont-a-for-drooling-in-children-a-systematic-review-and-meta-analysis
#13
REVIEW
Haresh Oad, Alix Maltezeanu, Sabrina D da Silva, Sam J Daniel
INTRODUCTION: Sialorrhea, also known as drooling, hypersalivation, or ptyalism, has a significant impact on the medical and psychosocial well-being of children. Onabotulinum toxin A (BoNT-A) is the most commonly used botulinum toxin worldwide for the treatment of sialorrhea in children. OBJECTIVES: To conduct a comprehensive systematic review and meta-analysis to assess the clinical efficacy and potential adverse effects of BoNT-A as a treatment for drooling in children...
January 31, 2024: Laryngoscope
https://read.qxmd.com/read/38264389/a-palliative-care-approach-to-amyotrophic-lateral-sclerosis
#14
JOURNAL ARTICLE
Cláudio Gouveia, Licínia Araújo, Susete Freitas, João Correia, Vilma Passos, Graciela Camacho, Luísa Gomes, Helena Fragoeiro, Cristiana Camacho, Beatriz Chambino
INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a degenerative disease characterized by motor dysfunction. Currently, treatment options are limited and management is based mostly on symptom control and quality of life optimization, so palliative care plays a fundamental role. Our objective was to characterize the ALS population in Madeira Island that was referenced and/or followed by a palliative care unit over a five-year period. METHODS: Longitudinal, retrospective, descriptive, and observational study to analyze patients with ALS who were referred and/or followed by a palliative care unit during a five-year period, between 2017 and 2021...
December 2023: Curēus
https://read.qxmd.com/read/38186486/the-challenge-of-managing-refractory-psychosis-amid-multiple-medication-side-effects-a-case-report-and-review-of-the-literature
#15
Alejandro Rodulfo, Sabina Goldstein, Zina Meriden
Antipsychotics are the mainstay for the treatment of schizophrenia and other psychotic disorders; however, these agents are associated with an extensive side effect profile that may complicate treatment outcomes. We present the case of a 35-year-old woman with a history of schizoaffective disorder and five prior psychiatric hospitalizations. The patient first presented to the hospital for disorganized behavior, in addition to poor sleep, auditory hallucinations, and racing thoughts in the context of medication nonadherence...
December 2023: Curēus
https://read.qxmd.com/read/38131516/management-of-neurological-problems-in-children-on-home-invasive-mechanical-ventilation
#16
JOURNAL ARTICLE
Yavuz Sayar, Miraç Yıldırım, Serap Teber
INTRODUCTION: Home invasive mechanical ventilation (HIMV) has become a crucial long-term respiratory support for children with neurological disorders, but requires advanced technological skills and 24-h care. The increasing global population of children on HIMV is attributed to advancements in intensive care and improved survival rates. METHOD: The manuscript will review the most common neurological problems encountered in children on HIMV. CONCLUSION: The manuscript emphasizes the multidisciplinary nature of managing these patients, involving pediatric pulmonologists, pediatric neurologists, pediatric intensivists, nurses, therapists, dietitians, psychologists, and caregivers...
December 22, 2023: Pediatric Pulmonology
https://read.qxmd.com/read/38130339/ophthalmic-atropine-a-typical-anticholinergic-toxidrome-from-an-atypical-old-culprit
#17
JOURNAL ARTICLE
Michael Raschka, Marshal Khant
Included on the World Health Organization Model Lists of Essential Medicines, atropine remains a cornerstone medication that is used for a myriad of clinical indications. Systemically, atropine carries indications for the treatment of asymptomatic and symptomatic bradycardia, reduction of salivation and bronchial secretions prior to surgery, and as an antidote for a variety of poisoning agents (i.e., carbamate or organophosphate insecticides, nerve agents, muscarine-containing mushrooms). Topically, atropine is administered via the ophthalmic route for the treatment of cycloplegia, mydriasis, and amblyopia or may be administered sublingually to treat chronic sialorrhea...
2023: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/38100776/evaluation-and-comparison-of-the-effectiveness-of-atropine-eye-drops-ipratropium-bromide-nasal-spray-and-amitriptyline-tablet-in-the-management-of-clozapine-associated-sialorrhea-in-patients-with-refractory-schizophrenia-a-randomized-clinical-trial
#18
RANDOMIZED CONTROLLED TRIAL
Fatemeh Mohammad-Gholizad, Iman Karimzadeh, Ebrahim Moghimi-Sarani, Mahdi Arshadi, Negar Mortazavi
PURPOSE: Clozapine, a second-generation antipsychotic medication, is mainly indicated for managing treatment-resistant schizophrenia. Among all the nonthreatening adverse effects of clozapine, sialorrhea is a stigmatizing complication occurring in approximately 31.0% to 97.4% of patients. In this study, 2 topical agents (atropine eye drop and ipratropium nasal spray) and a systemic medication (amitriptyline) were compared simultaneously for the management of clozapine-associated sialorrhea...
January 2024: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/38056063/botulinum-toxin-treatment-in-parkinsonism
#19
REVIEW
Charenya Anandan, Joseph Jankovic
Botulinum toxin (BoNT) was approved by the United States Food and Drug Administration (FDA) in 1989 for facial movement disorders and strabismus, but since that time its indications have been expanding beyond neurologic and ophthalmologic disorders. This article is a narrative review of the therapeutic use of BoNT in tremors, dystonia, sialorrhea, bladder and other autonomic symptoms, levodopa-induced dyskinesia and other problems occuring in the setting of parkinsonism. Though FDA approval is lacking for some of these indications, expert experiences have shown that BoNT is often beneficial in this group of patients...
January 15, 2024: Journal of the Neurological Sciences
https://read.qxmd.com/read/38044765/orofacial-uses-of-botox-in-dentistry-and-their-associated-risks-a-population-based-cross-sectional-study-in-saudi-arabia
#20
JOURNAL ARTICLE
A K Demyati, A A Nassar
BACKGROUND: Various healthcare professionals, including dentists, provide botulinum toxin (Botox) for cosmetic and therapeutic treatment. In dentistry, it has multiple uses, such as gummy smile, bruxism, sialorrhea, muscle spasm, and orofacial pain, yet unwanted side effects may arise. AIMS: This study aimed to investigate the participants' perspective regarding the scope of Botox in dentistry and its associated risk, provider involvement, and factors affecting the choice of which healthcare professions administer Botox injections in Saudi Arabia...
November 1, 2023: Nigerian Journal of Clinical Practice
keyword
keyword
6366
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.